-
1.发明公开USE OF AN FGF-21 COMPOUND AND A GLP-1 COMPOUND FOR THE TREATMENT OF OBESITY 有权VERWENDUNG EINER FGF-21-VERBINDUNG UND GLP-1-VERBINDUNG ZUR BEHANDLUNG VON ADIPOSTIAS
公开(公告)号：EP2185178A2
公开(公告)日：2010-05-19
申请号：EP08796800.4
申请日：2008-07-30
发明人： COSKUN, Tamer , GLAESNER, Wolfgang
CPC分类号： A61K38/26 , A61K38/1825 , A61K2300/00
摘要： The present invention provides methods of lowering body weight by administering an FGF-21 compound in combination with a GLP-1 compound. In addition, the present invention also provides methods to treat obesity by administering an FGF-21 compound in combination with a GLP-1 compound. The present invention also discloses combinations useful in the methods of the present invention.
摘要翻译： 本发明提供了通过与GLP-1化合物组合施用FGF-21化合物来降低体重的方法。 此外，本发明还提供了通过与GLP-1化合物组合施用FGF-21化合物来治疗肥胖症的方法。 本发明还公开了可用于本发明方法的组合。
-
公开(公告)号：EP1751184B1
公开(公告)日：2009-09-30
申请号：EP05742237.0
申请日：2005-05-02
CPC分类号： C07K14/50 , A61K38/00 , C07K2319/30 , C07K2319/31 , C07K2319/75
-
3.发明授权USE OF AN FGF-21 COMPOUND AND A GLP-1 COMPOUND FOR THE TREATMENT OF OBESITY 有权使用FGF-21化合物和GLP-1化合物治疗肥胖症
公开(公告)号：EP2185178B1
公开(公告)日：2017-08-23
申请号：EP08796800.4
申请日：2008-07-30
发明人： COSKUN, Tamer , GLAESNER, Wolfgang
CPC分类号： A61K38/26 , A61K38/1825 , A61K2300/00
-
公开(公告)号：EP1641823B1
公开(公告)日：2011-09-21
申请号：EP04752589.4
申请日：2004-06-10
IPC分类号： C07K14/605 , C12N15/62 , A61P3/10 , A61K38/26
CPC分类号： C07K16/26 , A61K38/00 , C07K14/503 , C07K14/605 , C07K2319/30
摘要： The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.
-
公开(公告)号：EP1753780A1
公开(公告)日：2007-02-21
申请号：EP05749168.0
申请日：2005-05-19
发明人： BOKVIST, Bengt Krister, Lilly Forschung GmbH , CUMMINS, Robert, Chadwick , GLAESNER, Wolfgang , GROMADA, Jesper Lindgren, Lilly Forschung GmbH , MAYER, John, Philip , ZHANG, Lianshan , ALSINA-FERNANDEZ, Jorge
IPC分类号： C07K14/575
CPC分类号： C07K14/57563
摘要： The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
-
公开(公告)号：EP1432730A2
公开(公告)日：2004-06-30
申请号：EP02756392.3
申请日：2002-08-14
IPC分类号： C07K14/435 , C07K14/605 , A61K38/16 , A61K38/26
CPC分类号： C07K14/605 , A61K38/00
摘要： Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 7, 8, 12, 16, 18, 19, 20, 22, 25, 27, 30, 33, and 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 compounds are also disclosed.
-
公开(公告)号：EP1881850B1
公开(公告)日：2010-09-29
申请号：EP06759598.3
申请日：2006-05-11
发明人： ZHANG, Lianshan , VICK, Andrew, Mark , MILLICAN, Rohn, Lee, Junior , MAYER, John, Philip , GLAESNER, Wolfgang
IPC分类号： A61K47/48 , C07K14/605 , A61P3/10
CPC分类号： C07K14/605 , A61K47/60
摘要： The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating conditions or disorders benefited by lowering blood glucose, decreasing food intake, decreasing gastric or intestinal emptying, increasing beta (ß) cell population, or decreasing gastric or intestinal motility.
-
公开(公告)号：EP1753780B1
公开(公告)日：2008-03-19
申请号：EP05749168.0
申请日：2005-05-19
发明人： BOKVIST, Bengt Krister, Lilly Forschung GmbH , CUMMINS, Robert, Chadwick , GLAESNER, Wolfgang , GROMADA, Jesper Lindgren, Lilly Forschung GmbH , MAYER, John, Philip , ZHANG, Lianshan , ALSINA-FERNANDEZ, Jorge
IPC分类号： C07K14/575
CPC分类号： C07K14/57563
摘要： The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
-
公开(公告)号：EP1294757B1
公开(公告)日：2006-11-22
申请号：EP01939252.1
申请日：2001-06-01
IPC分类号： C07K14/605 , A61K38/26 , A61P3/10
CPC分类号： A61K38/26 , C07K14/47 , C07K14/605
摘要： Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 11, 12, 16, 22, 23, 24, 25, 27, 30, 33, 34, 35, 36, or 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 compounds are also disclosed.
-
公开(公告)号：EP1641823A2
公开(公告)日：2006-04-05
申请号：EP04752589.4
申请日：2004-06-10
IPC分类号： C07K14/605 , C12N15/62 , A61P3/10 , A61K38/26
CPC分类号： C07K16/26 , A61K38/00 , C07K14/503 , C07K14/605 , C07K2319/30
摘要： The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.
-
-
-
-
-
-
-
-
-
搜索结果
28 条记录 (耗时 0.018 秒)
